Beda Pharmaceuticals Class 1 new drug BET inhibitors were approved clinically

Screenshot Source: CDE Official Website According to the announcement issued by Beda Pharmaceuticals, BPI-23314 is a new molecular solid compound developed by it, is a new type of strong, selective bromine domain and oral small molecule inhibitor of the end extraterrestrual domain (BET) protein family, with a new mechanism for the degradation of target protein, intended for the treatment of tumors such as hematoma, breast cancer and lung cancer.
BET protein is widely expressed in human tissue and is involved in the regulation of gene transcription.
study found that abnormal expression and dysfunction of BET protein are associated with a variety of diseases, especially the occurrence, immersion, metastasis and other processes of tumors.
as a potential anti-tumor target, BET family protein has been widely concerned and developed in recent years.
public data show that BPI-23314 can inhibit the function of BET family proteins by specificity, regulate the transcriptional expression of cancer-related genes, and then affect cell growth, proliferation, apoptosis and other physiological processes, and ultimately achieve the goal of inhibiting tumor growth.
according to The Bayda Pharmaceuticals Announcement, at present, the same target drugs in China and a foreign country are in the clinical trial stage, there is no drug market, BPI-23314 belongs to the domestic and foreign are not listed innovative drugs.
March 2019, BPI-23314 obtained CDE approval to conduct clinical trials of single-drug tumors in the malignant blood system.
, according to the China Drug Clinical Trial Registration and Information Disclosure Platform, Beda Pharmaceuticals is currently conducting a Phase 1 one-arm trial.
this is a phase 1 study evaluating the safety, toerability and pharmacodynamics of single and continuous drug supply in patients with relapsed/refractic acute myeloid leukemia.
the main purpose of the study was to assess the safety and tolerance of BPI-23314 tablets in patients with relapsed/refrased acute myeloid leukemia, and to explore the maximum to-dosage (MTD) to determine the recommended dose (RP2D) for phase 2 studies.
the study is currently being recruited by the subjects.
BPI-23314 was approved again for clinical use in advanced malignant solid tumors.
also means that this oral small molecule BET inhibitor is about to be clinically studied in a wider patient population.
we wish these studies well and bring innovative therapies to patients at an early time.